Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

CONCLUSION: In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.PMID:38070191 | DOI:10.1093/oncolo/oyad317

Source: The Oncologist - December 9, 2023 Category: Cancer & Oncology Authors: Jason A Mouabbi Wei Qaio Yu Shen Akshara Singareeka Raghavendra Debasish Tripathy Rachel M Layman Source Type: research